AI in healthcare is no longer a future-state promise. It’s a $37 billion market in 2026, growing at a CAGR of more than 44% toward a projected $613 billion by 2034. Sixty-six percent of physicians now use health AI tools — a 78% jump from just 38% in 2023. And the average ROI for AI…
Five major trends are reshaping AI product development in 2026 — from agentic AI moving to production, to the collapse of inference costs and the rise of AI governance as a product requirement.
What Does “Build vs. Buy AI” Actually Mean in 2026? Build vs. buy AI is the strategic decision every business leader faces when adopting artificial intelligence: do you invest in developing a custom AI solution from scratch, or do you purchase an off-the-shelf platform and adapt it to your needs? In 2026, the answer is…
AI in fintech is a $45B market in 2026 with 92% of financial firms investing. Here are the use cases that work, why most products stall, and the governance-first playbook we use at Neomeric.
AI in healthcare is delivering real results in 2026 — from clinical documentation and diagnostics to drug discovery and clinical trials. Here is where the technology is making the biggest impact, what adoption really looks like, and what organisations need to get right when building AI-powered health products.
RAG and fine-tuning are both ways to make AI smarter about your specific domain — but they work very differently and suit very different problems. Here’s how to decide which one you need.